Pyridinolcarbamate in the Treatment of Ischemic Heart Diseases: A Double Blind Study

Thirty-four out-patients with electrocardiographic evidence of ischemic heart disease were divided into 2 groups, each group comprising of patients closely matched as to variables of sex, age, severity of symptoms and ECG findings. One group received pyridinolcarbamate, 1, 500mg. in 3 divided doses, while the other group received placebo. The response to the therapy in each group was evaluated on the basis of (a) physical work capacity (PWC) (b) nitroglycerine requirement and (c) electrocardiogram. The group that received pyridinolcarbamate showed a statistically significant (p